Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
暂无分享,去创建一个
K. Hagiwara | M. Kanazawa | H. Miyazawa | A. Sutani | Kiyoko Kobayashi | K. Udagawa | K. Kobayashi | Y. Murayama | T. Tanaka | N. Koyama | Y. Nagai | Y. Uchida | M. Kanazawa | Y. Uchida | M. Nagata | T. Tanaka | Michio Nagata | Tomoaki Tanaka
[1] F. Hirsch,et al. Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Ladanyi,et al. Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.
[3] Patricia L. Harris,et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Kevin Carroll,et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.
[5] T. Shibata,et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Schellens,et al. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). , 2005, The oncologist.
[7] Huqun,et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. , 2005, Cancer research.
[8] Mayumi Ono,et al. Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas , 2005, Clinical Cancer Research.
[9] William Pao,et al. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Takayuki Kosaka,et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] F. Hirsch,et al. Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer , 2005, Current opinion in oncology.
[12] R. Twombly. Failing survival advantage in crucial trial, future of Iressa is in jeopardy. , 2005, Journal of the National Cancer Institute.
[13] S. Toyooka,et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] György Kéri,et al. Cellular targets of gefitinib. , 2005, Cancer research.
[15] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[16] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[17] David Cella,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.
[18] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] G. Verleden,et al. Prognostic factors in nonsmall cell lung cancer , 2002 .
[20] M. Brundage,et al. Prognostic factors in non-small cell lung cancer: a decade of progress. , 2002, Chest.
[21] 徳毛 誠樹. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers , 2005 .
[22] K. Arar,et al. Real-time genotyping with oligonucleotide probes containing locked nucleic acids. , 2004, Analytical biochemistry.